Oncologic Outcomes Based on Clinical Pattern of Preoperative PET-CT in Resected Pancreatic Cancer

Oncologic Outcomes Based on Clinical Pattern of Preoperative PET-CT in Resected Pancreatic Cancer-Prospective Cohort Study

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03077334

Enrollment

200

Registered

2017-03-10

Start date

2014-10-07

Completion date

2018-09-17

Last updated

2019-01-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pancreatic Cancer

Brief summary

The 18F-FDG-PET scan is currently being used for cancer diagnosis, staging, identifying hidden metastasis, and assessment of treatment responses in clinical oncology. Although there are important studies suggesting potential associations between PET-based parameters and oncologic outcomes, the calculation and official documentation of individual PET-based parameters might not be routine in clinical practice because these processes usually require time- and labor-consuming processes for the radiologists. In this study, the investigators prospectively determined clinical 18F-FDG-PET type according to degree of FDG-uptake in pancreatic cancer and compare oncologic outcomes between the types.

Interventions

DEVICEPET-CT

PET-CT will be done before operation and that is routine treatment procedure for pancreatic cancer.

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

20 Years to 80 Years

Healthy volunteers

Inclusion criteria

* Candidate for radical pancreatectomy due to pancreatic cancer without neoadjuvant treatment * Age between 20 years old and 80 years old * General performance status greater than 70 * Results of peroperative PET-CT available

Exclusion criteria

* Unresectable, locally advance and metastatic pancreatic cancer * Patients not wanting operation * ASA score of greater than 3 * History of chronic alcoholism ot drug abuse * Lack of patient compliance * Patients not agreeing to enroll in the study. * Patients unable to understand and sign the study agreement. * History of neoadjuvant treatment

Design outcomes

Primary

Measure	Time frame	Description
Clinical PET type assessed by surgeons from preoperatively preformed PET imaging	1 week after surgery	Three surgeons will review the preoperative PET imaging and each will determine the clinical PET type as either K-type or Non-K type. Inter-surgeon agreement of clinical PET type will be determined. Clinicopathologic characteristics between K-type and Non-K type will also be analyzed.

Secondary

Measure	Time frame
Number of patients with recurrence of cancer or mortality from cancer following operation	3 years

Countries

South Korea

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026